Difference between revisions of "Divarasib (GDC-6036)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/divarasib NCI Drug Dictionary]: An orally available inhibitor of the oncogen...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/divarasib NCI Drug Dictionary]: An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/divarasib NCI Drug Dictionary]: An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. | ||
| + | |||
| + | *[https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11963 IUPHAR/BPS] | ||
==Preliminary data== | ==Preliminary data== | ||
| Line 6: | Line 8: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code | + | *'''Code names:''' GDC-6036, RG-6330 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 14:59, 17 November 2023
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, divarasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling.
Preliminary data
- GO42144: Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721. link to original article PubMed NCT04449874
Also known as
- Code names: GDC-6036, RG-6330